MX2020003939A - Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. - Google Patents

Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.

Info

Publication number
MX2020003939A
MX2020003939A MX2020003939A MX2020003939A MX2020003939A MX 2020003939 A MX2020003939 A MX 2020003939A MX 2020003939 A MX2020003939 A MX 2020003939A MX 2020003939 A MX2020003939 A MX 2020003939A MX 2020003939 A MX2020003939 A MX 2020003939A
Authority
MX
Mexico
Prior art keywords
same
mdm2
therapeutic methods
mdm2 inhibitors
inhibitors
Prior art date
Application number
MX2020003939A
Other languages
English (en)
Inventor
Angelo Aguilar
Liu Liu
Jianfeng Lu
Donna Mceachern
Shaomeng Wang
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2020003939A publication Critical patent/MX2020003939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Abstract

Se divulgan inhibidores de MDM2 y proteínas relacionadas a MDM2 y composiciones que contienen los mismos. También se divulgan métodos para el uso de inhibidores de MDM2 en el tratamiento de enfermedades y afecciones en donde la inhibición de una interacción entre p53 y MDM2 proporciona un beneficio, como en el caso del cáncer.
MX2020003939A 2014-04-17 2016-10-13 Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. MX2020003939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461980747P 2014-04-17 2014-04-17

Publications (1)

Publication Number Publication Date
MX2020003939A true MX2020003939A (es) 2020-08-13

Family

ID=54321424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013457A MX2016013457A (es) 2014-04-17 2015-04-16 Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2020003939A MX2020003939A (es) 2014-04-17 2016-10-13 Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016013457A MX2016013457A (es) 2014-04-17 2015-04-16 Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.

Country Status (12)

Country Link
US (1) US9745314B2 (es)
EP (1) EP3131544B1 (es)
JP (2) JP6694827B2 (es)
KR (2) KR102599945B1 (es)
CN (2) CN106794171B (es)
AU (1) AU2015247646B2 (es)
CA (1) CA2945527C (es)
ES (1) ES2712973T3 (es)
IL (2) IL248211B (es)
MX (2) MX2016013457A (es)
SG (2) SG11201608667SA (es)
WO (1) WO2015161032A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2015161032A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
US9962380B2 (en) * 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3087110A1 (en) * 2017-12-29 2019-07-04 Gan & Lee Pharmaceuticals Compounds capable of being used as tumor inhibitor, preparation method thereof, and application thereof
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
EA202091964A1 (ru) * 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
EP3672591B1 (en) 2018-07-31 2024-02-14 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020030016A1 (en) * 2018-08-08 2020-02-13 Ascentage Pharma (Suzhou) Co., Ltd. Combination of immunotherapies with mdm2 inhibitors
WO2020103922A1 (en) 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
KR20210003178A (ko) * 2018-12-14 2021-01-11 어센테지 파마 (쑤저우) 컴퍼니 리미티드 골관절염을 치료하기 위한 화합물
WO2020169073A1 (en) * 2019-02-24 2020-08-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
WO2021004516A1 (en) * 2019-07-11 2021-01-14 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing 2-indolinospirone compound and intermediate thereof
WO2021013028A1 (en) * 2019-07-19 2021-01-28 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2021018032A1 (en) * 2019-07-26 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
CN112852959A (zh) * 2019-11-27 2021-05-28 苏州亚盛药业有限公司 用于预测靶向细胞凋亡途径的化合物的抗癌功效的方法和组合物
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN113149998A (zh) * 2020-01-23 2021-07-23 苏州亚盛药业有限公司 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
WO2021175192A1 (en) * 2020-03-02 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
WO2021208911A1 (en) * 2020-04-14 2021-10-21 Ascentage Pharma (Suzhou) Co., Ltd. Novel medical use of mdm2 inhibitors
US20230218575A1 (en) * 2020-06-15 2023-07-13 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeautic applications thereof
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022170108A1 (en) * 2021-02-04 2022-08-11 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof in prevention of radiation injury
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023011488A1 (zh) 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116421598A (zh) * 2022-01-11 2023-07-14 苏州亚盛药业有限公司 用于治疗aml-mrc和mds的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
EP2311814A1 (en) 2005-12-01 2011-04-20 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
ES2350504T3 (es) * 2006-03-13 2011-01-24 F. Hoffmann-La Roche Ag Derivados de espiroindolinona.
CA2644758A1 (en) * 2006-03-13 2007-09-20 F. Hoffmann-La Roche Ag Spiroindolinone derivatives
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
AU2007297823B2 (en) * 2006-08-30 2012-04-19 The Regents Of The University Of Michigan New small molecule inhibitors of MDM2 and the uses thereof
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
US20080188506A1 (en) * 2007-02-07 2008-08-07 Qingjie Ding Spiroindolinone derivatives
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
CN104876938A (zh) * 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
EP2563360A4 (en) * 2010-04-09 2015-12-16 Univ Michigan BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN DISEASE TREATMENT
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
SG193002A1 (en) * 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
EP2707372B1 (en) * 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
KR102447057B1 (ko) * 2013-09-04 2022-09-23 다이이찌 산쿄 가부시키가이샤 스피로옥시인돌 유도체의 제조 방법
WO2015161032A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same

Also Published As

Publication number Publication date
EP3131544B1 (en) 2018-12-12
CA2945527C (en) 2022-05-17
US20150299211A1 (en) 2015-10-22
NZ724963A (en) 2021-10-29
AU2015247646A1 (en) 2016-10-27
KR102599945B1 (ko) 2023-11-09
MX2016013457A (es) 2017-05-04
JP2020100662A (ja) 2020-07-02
KR102389552B1 (ko) 2022-04-22
IL248211B (en) 2019-10-31
WO2015161032A1 (en) 2015-10-22
CN111718354A (zh) 2020-09-29
KR20160136450A (ko) 2016-11-29
SG11201608667SA (en) 2016-11-29
CA2945527A1 (en) 2015-10-22
ES2712973T3 (es) 2019-05-17
JP6694827B2 (ja) 2020-05-20
CN106794171B (zh) 2020-03-24
EP3131544A4 (en) 2017-08-30
JP2017511360A (ja) 2017-04-20
EP3131544A1 (en) 2017-02-22
SG10201913742TA (en) 2020-03-30
KR20220054697A (ko) 2022-05-03
IL269462B (en) 2021-05-31
CN106794171A (zh) 2017-05-31
IL248211A0 (en) 2016-11-30
AU2015247646B2 (en) 2019-06-06
IL269462A (en) 2019-11-28
US9745314B2 (en) 2017-08-29
JP6909323B2 (ja) 2021-07-28

Similar Documents

Publication Publication Date Title
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
CA2956871C (en) Compounds active towards bromodomains
MX2018005377A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
TW201613648A (en) Compounds and compositions for immunotherapy
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
GB2541571A (en) Pharmaceutical compositions
EP3153169A4 (en) Method for treating tumour, pharmaceutical composition and medicine box kit
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
IN2014MU00303A (es)
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
ZA201703467B (en) Methods of treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3463398A4 (en) IMMUNITY CHECKPOINT INHIBITORS AND CYTOTOXIC T CELLS FOR TREATING CANCER
EP3452044A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12016501838A1 (en) Compounds and their methods of use
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT